Evidence map›Paper›PMID 40346061›Full record

ArticleNature communications2025

A general assay platform to study protein pharmacology using ligand-dependent structural dynamics.

Daniel A Ciulla, Patricia K Dranchak, Mahesh Aitha, Renier H P van Neer, Divia Shah, Ravi Tharakan, Kelli M Wilson, Yuhong Wang, John C Braisted, James Inglese

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. A Hybrid Experimental and in silico Platform for ITPK1 Chemical Probe Discovery.SLAS discovery : advancing life sciences R & D · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel A Ciulla *Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-0365-2667
Patricia K Dranchak *Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-1349-4885
Mahesh AithaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.
Renier H P van NeerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-9131-3824
Divia ShahDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.
Ravi TharakanDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.
Kelli M WilsonDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.ORCID http://orcid.org/0000-0003-2636-2766
Yuhong WangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.
John C BraistedDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.
James IngleseDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA. jinglese@mail.nih.gov.ORCID http://orcid.org/0000-0002-7332-5717

Funding

Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead DiscoveryZIATR000053 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI INGLESE, JAMES · 2015 to 2025
$4.5M
Intramural NIH HHS ZIA TR000053U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) 1ZIATR000053
6 · The paper itself

Abstract

Drug design strategies represent a fundamental challenge in chemical biology that could benefit from the development of next-generation high-throughput assays. Here we demonstrate that structural dynamic changes induced by ligand binding can be transmitted to a sensor protein fused to a target protein terminus. Here, NanoLuc luciferase, used as the intact protein or its α-complementation peptide, was fused to seven proteins from distinct enzyme superfamilies resulting in sensitive ligand-dependent bioluminescent outputs. This finding allows a general non-competitive, function-independent, quantitative, isothermal gain-of-signal ligand binding readout. As applied to chemical library high throughput screening, we can observe multivariate pharmacologic outputs including cofactor-induced synergy in ligand binding, as well as an example of allosteric site binding. The structural dynamics response assay format described here can enable the investigation of proteins precluded from study due to cost-prohibitive, insensitive, or technically challenging assays, including from cell lysates containing endogenously expressed gene edited proteins.

Indexed as

High-Throughput Screening AssaysProteinsAllosteric SiteDrug DesignHumansLigandsLuciferasesLuminescent MeasurementsProtein BindingLigandsLuciferasesProteins

Identifiers

PMID40346061
PMCPMC12064818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.